Full Breakdown
ESA Partners with Siloton to Tackle Space-Induced Vision Loss
8/10/2026, 7:57:35 PM
Core Initiative
The European Space Agency (ESA) has engaged the UK-based eye-scanning startup Siloton to develop a compact diagnostic tool aimed at detecting and eventually preventing Spaceflight-Associated Neuro-Ocular Syndrome (SANS). The collaboration seeks a photonic-chip device, smaller than a coin, that can perform the same functions as conventional optometrist equipment but be usable in the microgravity environment of future Artemis lunar missions and other deep-space flights.
Background and Context
SANS comprises a set of eye and brain changes that arise during prolonged exposure to low-gravity conditions. NASA reports that roughly 70 % of astronauts aboard the International Space Station experience some form of the syndrome. A notable example is astronaut John Phillips, who entered the ISS in 2005 with 20/20 vision and returned after six months with vision reduced to 20/100. The condition is linked to fluid redistribution in the body that, without gravity, accumulates in the head, compressing the eyeballs, swelling the optic nerve, and shifting the retina forward.
Technology Development
Siloton, founded by physicists in 2020, already collaborates with the United Kingdom’s National Health Service to enable home-based retinal scans for patients with eye disorders. ESA’s requirements mirror those of the NHS but must accommodate the unique constraints of spaceflight, according to co-founder and chief technology officer Euan Allen. The company’s approach leverages quantum-based photonic chips to miniaturize the core components of eye-testing hardware.
Official Outlook
ESA officials state that the partnership is intended to generate data that could inform both treatment protocols and preventive measures for astronauts on longer missions. By integrating Siloton’s technology into spacecraft, the agency hopes to monitor crew vision in real time and intervene before permanent damage occurs.
Why It Matters
As space agencies plan missions beyond low Earth orbit, understanding and mitigating SANS becomes critical to crew health and mission success. A portable, high-precision eye-scan could reduce the risk of lasting visual impairment, supporting the viability of extended lunar stays and eventual journeys to Mars.
